HALO logo

Halozyme Therapeutics (HALO) Return On Assets

Annual ROA

23.39%
+7.64%+48.51%

December 31, 2024

Summary

Performance

1-Year Change

+48.51%

3-Year Change

-51.09%

5-Year Change

+262.88%

15-Year Change

+45.1%

HALO ROA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.88%
HALO annual return on assets is higher than 98.88% of companies in Healthcare sector

High & Low

All-time High

47.82%
HALO annual return on assets is currently -51.09% below its historical high of 47.82%

3-Year Low

13.72%
HALO annual return on assets is currently +70.48% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
HALO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
HALO next annual earnings announcement has not yet been scheduled

OtherHALOprofitabilitymetrics:

Annual Revenue

$1.02 B
HALO annual revenue is $1.02 billion

Annual Net Income

$444.09 M
HALO annual net profit is $444.09 million

Annual EPS

$3.43
HALO annual earnings per share is $3.43

Annual ROE

198.42%
HALO annual return on equity is 198.42%

Quarterly ROA

22.83%
+2.29%+11.15%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+45.6%

3-Year Change

+63.77%

5-Year Change

+63.77%

HALO Quarterly ROA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.45%
HALO quarterly return on assets is higher than 98.45% of companies in Healthcare sector

High & Low

All-time High

47.77%
HALO quarterly return on assets is currently -52.21% below its historical high of 47.77%

3-Year Low

10.88%
HALO quarterly return on assets is currently +109.83% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
HALO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
HALO next earnings announcement is scheduled for May 7, 2025

OtherHALOprofitabilitymetrics:

Quarterly Revenue

$298.01 M
HALO quarterly revenue is $298.01 million

Quarterly Net Income

$137.01 M
HALO quarterly net profit is $137.01 million

Quarterly EPS

$1.06
HALO quarterly earnings per share is $1.06

Quarterly ROE

162.37%
HALO quarterly return on equity is 162.37%

ROA Formula

ROA =  Net Income
Total Assets ✕ 100%

Annual ROA

23.39%
HALO annual return on assets is 23.39%

Annual Net Income

$444.09 M
HALO annual net profit is $444.09 million

Annual Total Assets

$2.06 B
HALO annual total assets is $2.06 billion

HALO ROA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+48.5%+45.6%
3 y3 years-51.1%+63.8%
5 y5 years+262.9%+63.8%

HALO ROA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-51.1%+70.5%-44.9%+109.8%
5 y5-year-51.1%+262.9%-52.2%+229.6%
alltimeall time-51.1%+102.7%-52.2%+101.2%

Halozyme Therapeutics ROA History

DateAnnualQuarterly
Dec 2024
23.39%(+48.5%)
22.83%(+11.1%)
Sep 2024
-
20.54%(+12.6%)
Jun 2024
-
18.24%(+2.7%)
Mar 2024
-
17.76%(+13.3%)
Dec 2023
15.75%(+14.8%)
15.68%(+12.5%)
Sep 2023
-
13.94%(+7.3%)
Jun 2023
-
12.99%(+19.4%)
Mar 2023
-
10.88%(-16.5%)
Dec 2022
13.72%(-71.3%)
13.03%(-12.4%)
Sep 2022
-
14.88%(-49.1%)
Jun 2022
-
29.25%(-26.8%)
Mar 2022
-
39.94%(-3.5%)
Dec 2021
47.82%(+112.3%)
41.41%(-13.3%)
Sep 2021
-
47.77%(+51.4%)
Jun 2021
-
31.56%(+19.6%)
Mar 2021
-
26.39%(+10.0%)
Dec 2020
22.53%(-256.9%)
24.00%(+453.0%)
Sep 2020
-
4.34%(-151.9%)
Jun 2020
-
-8.36%(-52.5%)
Mar 2020
-
-17.61%(+8.4%)
Dec 2019
-14.36%(-14.2%)
-16.25%(+70.9%)
Sep 2019
-
-9.51%(-2.0%)
Jun 2019
-
-9.70%(-13.2%)
Mar 2019
-
-11.18%(-33.9%)
Dec 2018
-16.73%(-203.8%)
-16.91%(-269.6%)
Sep 2018
-
9.97%(-42.7%)
Jun 2018
-
17.40%(-1.1%)
Mar 2018
-
17.59%(-4.5%)
Dec 2017
16.12%(-134.7%)
18.41%(-161.4%)
Sep 2017
-
-29.98%(-29.5%)
Jun 2017
-
-42.50%(+0.7%)
Mar 2017
-
-42.19%(+9.0%)
Dec 2016
-46.48%(+150.7%)
-38.70%(+33.3%)
Sep 2016
-
-29.03%(-2.7%)
Jun 2016
-
-29.84%(+58.8%)
Mar 2016
-
-18.79%(-2.1%)
Dec 2015
-18.54%(-63.7%)
-19.19%(-24.5%)
Sep 2015
-
-25.42%(+14.2%)
Jun 2015
-
-22.25%(-32.0%)
Mar 2015
-
-32.74%(-22.2%)
Dec 2014
-51.07%(-27.7%)
-42.10%(-25.2%)
Sep 2014
-
-56.25%(-6.5%)
Jun 2014
-
-60.15%(-16.0%)
Mar 2014
-
-71.57%(-2.1%)
Dec 2013
-70.59%
-73.11%(+28.1%)
Sep 2013
-
-57.09%(+0.9%)
DateAnnualQuarterly
Jun 2013
-
-56.57%(+20.7%)
Mar 2013
-
-46.85%(-1.2%)
Dec 2012
-53.42%(+112.2%)
-47.40%(-28.7%)
Sep 2012
-
-66.44%(+53.6%)
Jun 2012
-
-43.26%(+53.9%)
Mar 2012
-
-28.11%(+15.4%)
Dec 2011
-25.17%(-60.2%)
-24.36%(+17.6%)
Sep 2011
-
-20.72%(-52.1%)
Jun 2011
-
-43.30%(-34.0%)
Mar 2011
-
-65.61%(-5.0%)
Dec 2010
-63.20%(-16.8%)
-69.05%(+7.2%)
Sep 2010
-
-64.44%(-4.0%)
Jun 2010
-
-67.14%(-4.6%)
Mar 2010
-
-70.40%(-2.3%)
Dec 2009
-75.93%(+40.5%)
-72.04%(-5.8%)
Sep 2009
-
-76.50%(+5.7%)
Jun 2009
-
-72.35%(+12.0%)
Mar 2009
-
-64.58%(+19.0%)
Dec 2008
-54.05%(+69.1%)
-54.28%(+29.0%)
Sep 2008
-
-42.08%(+15.8%)
Jun 2008
-
-36.33%(+16.8%)
Mar 2008
-
-31.10%(+13.9%)
Dec 2007
-31.96%(-27.9%)
-27.31%(-1.8%)
Sep 2007
-
-27.80%(-11.1%)
Jun 2007
-
-31.28%(-25.7%)
Mar 2007
-
-42.11%(-31.4%)
Dec 2006
-44.30%(-38.4%)
-61.35%(-28.0%)
Sep 2006
-
-85.18%(-8.8%)
Jun 2006
-
-93.35%(-1.4%)
Mar 2006
-
-94.67%(-1.4%)
Dec 2005
-71.93%(-32.5%)
-96.04%(-17.8%)
Sep 2005
-
-116.83%(+1.5%)
Jun 2005
-
-115.14%(+0.5%)
Mar 2005
-
-114.57%(-12.3%)
Dec 2004
-106.64%(-77.9%)
-130.71%(-36.7%)
Sep 2004
-
-206.43%(+26.7%)
Jun 2004
-
-162.88%(-10.3%)
Mar 2004
-
-181.49%(-80.9%)
Dec 2003
-481.88%(-45.5%)
-948.46%(-48.6%)
Sep 2003
-
-1843.54%(+39.9%)
Jun 2003
-
-1317.83%(+20.0%)
Mar 2003
-
-1097.84%(+33.7%)
Dec 2002
-884.09%(+481.2%)
-821.16%(+4469.6%)
Sep 2002
-
-17.97%(+148.5%)
Jun 2002
-
-7.23%(-129.2%)
Mar 2002
-
24.80%
Dec 2001
-152.11%
-

FAQ

  • What is Halozyme Therapeutics annual return on assets?
  • What is the all time high annual ROA for Halozyme Therapeutics?
  • What is Halozyme Therapeutics annual ROA year-on-year change?
  • What is Halozyme Therapeutics quarterly return on assets?
  • What is the all time high quarterly ROA for Halozyme Therapeutics?
  • What is Halozyme Therapeutics quarterly ROA year-on-year change?

What is Halozyme Therapeutics annual return on assets?

The current annual ROA of HALO is 23.39%

What is the all time high annual ROA for Halozyme Therapeutics?

Halozyme Therapeutics all-time high annual return on assets is 47.82%

What is Halozyme Therapeutics annual ROA year-on-year change?

Over the past year, HALO annual return on assets has changed by +7.64% (+48.51%)

What is Halozyme Therapeutics quarterly return on assets?

The current quarterly ROA of HALO is 22.83%

What is the all time high quarterly ROA for Halozyme Therapeutics?

Halozyme Therapeutics all-time high quarterly return on assets is 47.77%

What is Halozyme Therapeutics quarterly ROA year-on-year change?

Over the past year, HALO quarterly return on assets has changed by +7.15% (+45.60%)